Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort oleh Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Baranda, Weijing Sun, Stephen Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Rashna Madan, Hassan Abushukair, Kelly Mulvaney, Andrew K. Godwin, Azhar Saeed